Neurophth Overview
- Founded
- 2016
- Status
- Private
- Latest Deal Type
- Series A
- Latest Deal Amount
- $18.4M
- Investors
- 5
Neurophth General Information
Description
Developer of gene therapies for ophthalmological disorders. The company's therapies aim to cure disorders such as Leber's hereditary optic neuropathy caused by genetic mutation, enabling physicians to prescribe more effective treatments to their patients.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
- Room C270-C271, Floor 3, Building B1, Wuhan National Bio-industry Base
- No.666 Gaoxin Avenue, East Lake New Technology Development Zone
- Wuhan, Hubei 430000
- China
+86 027 0000 0000
Neurophth Timeline
Neurophth Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC (Series A) | 08-Apr-2020 | $18.4M | 000.00 | 0000 | Completed | Pre-Clinical Trials |
| 1. Early Stage VC | 16-Aug-2018 | Completed | Startup |
Neurophth Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Su Xiao | Chief Executive Officer & Founder |
Neurophth Investors (5)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Fosun InnoStar Venture | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| Sequoia Capital China | Venture Capital | Minority | 000 0000 | 000000 0 | |
| BGI Co-Win | Corporate Venture Capital | Minority | 000 0000 | 000000 0 | |
| BOHE Angel Fund | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Northern Light Venture Capital | Venture Capital | Minority | 000 0000 | 000000 0 |